medigraphic.com
Revista Médica Sinergia

2019, Number 08

Next >>

Revista Médica Sinergia 2019; 4 (08)

Correlation between serological and echographic markers to patients with non-alcoholic fatty liver and diabetes mellitus type 2

Quevedo RN, Pérez CR, Sánchez GIV

Language: Spanish
References: 57
Page:
PDF size: 824.66 Kb.


ABSTRACT

Introduction: Type 2 diabetics have a high risk of suffering from fatty liver disease alcoholic. Detection and early intervention may reduce cardiovascular risk, prevent their complications and reduce their progression. The objective is to evaluate the correlation between the markers by abdominal ultrasound and indirect serological markers in type 2 diabetic patients with non-alcoholic fatty liver.
Method: A descriptive, correlational and transversal study was carried out. Thirty three patients were studied to evaluate the severity of hepatic steatosis by abdominal ultrasound. The indirect serological markers were glycemia, total cholesterol, triglycerides, alanine transaminase, aspartate transaminase and ganmaglutamyl transferase. The results of both markers by Student's T test, Kolmogorov adjustment test and variance analysis.
Results: The average age was 54.9 ± 9.1 years. Moderate hyperechogenic marker (45.5%) with diffuse pattern was more frequently observed. The most altered indirect serological markers were glycemia (n = 29, 87.8%), triglycerides (n = 25, 75.8%), total cholesterol (n = 22,66.7) and alaninetransaminase (n = 21). 63.6%). The levels of glycemia and enzyme ASAT offered Rho Spearman values of r = 0.65 and r = 0.61 respectively.
Conclusion: The development of nonalcoholic fatty liver appears to be linked to chronic metabolic decompensation and insulin resistance. The levels of glycemia and ASAT enzyme were the indirect serological markers that had the highest statistical correlation with the degrees of liver injury diagnosed by abdominal ultrasound. It is recommended the use of predictive models from clinical variables, Indirect and ultrasound serological markers in the diagnosis and follow-up of patients with non-alcoholic fatty liver for its simplicity, and good correlation with more techniques complex. Risk stratification with the use of these tools enables implement early measures to reduce morbidity and mortality due to cardiovascular causes.


REFERENCES

  1. Velarde-Ruiz Velasco J, Mercado-Jáuregui L, Bocaletti-García M, Pinzón-Flores O, Barrientos-Ávalos J. Enfermedad hepática por hígado graso no alcohólico ¿Dónde estamos y hacia dónde vamos? Revista Médica MD. 2019; 10(2): p. 155-163.

  2. Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of Impaired Glucose Regulation in Patients with Non-Alcoholic Fatty Liver Disease. Experimental Diabetes Research. 2012; 2012: p. 1-7. https://doi.org/10.1155/2012/351974

  3. Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G. Nonalcoholic Fatty Liver Disease Is Associated with Aortic Valve Sclerosis in Patients with Type 2 Diabetes Mellitus. Sookoian SC. PLoS ONE. 2014 02 05; 9(2): e88371. https://doi.org/10.1371/journal.pone.0088371

  4. Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016 08; 65(8): p. 1136-1150. https://doi.org/10.1016/j.metabol.2015.09.017

  5. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology. 1990 Nov; 12(5) :1106-1110. https://doi.org/10.1002/hep.1840120505

  6. Lizardi-Cervera J, Becerra Laparra I, Chávez-Tapia NC, Ramos Ostos ME, Uribe Esquivel M. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Revista Gastroenterología Mexicana. 2006; 71(4): p. 453-459

  7. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. HARRISON. PRINCIPIOS DE MEDICINA INTERNA. 18th ed.: McGRAW-HILL INTERAMERICANA; 2012

  8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 02 22; 64(1): p. 73-84. https://doi.org/10.1002/hep.28431

  9. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. Clinical Gastroenterology and Hepatology. 2011 06; 9(6): 524-530.e1. https://doi.org/10.1016/j.cgh.2011.03.020

  10. Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. Longo DL. New England Journal of Medicine. 2017 Nov 23; 377(21): p. 2063-2072. https://doi.org/10.1056/nejmra1503519

  11. Ministerio de Salud Pública. Anuario Estadístico de Salud. La Habana:, Dirección de registros médicos y estadísticas de Salud; 2018. Aprox. 193 p

  12. Santiesteban Rodríguez M. Ultrasonido y Tomografía Axial Computarizada en el diagnóstico de la Esteatosis Hepática no Alcohólica. Tesis de Terminacion de Especialidad. La Habana: Hospinal Nacional "Hermanos Ameijeiras", Imagenología; 2013

  13. Elvírez G, Castellanos F, Santillán L, Dorta G, Galbán G, Arús S. Liver Stiffness Reference Values for Healthy Cuban Adults. MEDICC Review. 2018 January ; 20(1): p. 24-28

  14. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016 06; 64(6): p.1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004

  15. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 05 29; 55(6): p. 2005-2023. https://doi.org/10.1002/hep.25762

  16. Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, Torres M, Torán P, Caballería J. Hígado graso no alcohólico. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología. 2014 06; 37(6): p.372-383. https://doi.org/10.1016/j.gastrohep.2014.03.005

  17. Khov N. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2014; 20(22): 6821. https://doi.org/10.3748/wjg.v20.i22.6821

  18. Lee TH, Han† SH, Yang‡ JD, Kim‡ D, §, Ahmed∥ M. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver. 2013 05 15; 7(3): p.323-328. https://doi.org/10.5009/gnl.2013.7.3.323

  19. Goulart AC, Oliveira IRSD, Alencar AP, Santos MSCD, Santos IS, Martines BMR, Meireles DP, Martines JADS, Misciagna G, Benseñor IM, Lotufo PA. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Medical Journal. 2015 04; 133(2): p. 115-124. https://doi.org/10.1590/1516-3180.2014.9150812

  20. Machado MV. Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology. 2014; 20(36): 12956. https://doi.org/10.3748/wjg.v20.i36.12956

  21. Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol. 2012 Oct; 8(10): p.661-668

  22. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, Garg H, Chandan Kumar KN, Bihari C, Sarin SK. Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation. Digestive Diseases and Sciences. 2012 07 12; 58(1): p.265-274. https://doi.org/10.1007/s10620- 012-2306-1

  23. Satapathy S, Sanyal A. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease. 2015 09 17; 35(03): p.221-235. https://doi.org/10.1055/s-0035- 1562943

  24. Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View. Clinics in Liver Disease. 2018 02; 22(1): 11-21. https://doi.org/10.1016/j.cld.2017.08.003

  25. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. Gastroenterology. 2011 01; 140(1): 124-131. https://doi.org/10.1053/j.gastro.2010.09.038

  26. Sun B, Li Y, Lan Y. Fibroscan for diagnosis and treatment of chronic liver disease. World Chinese Journal of Digestology. 2015; 23(9): p.1433. https://doi.org/10.11569/wcjd.v23.i9.1433

  27. Graffigna M, Catoira N, Soutelo J, Azpelicueta A, Berg G, Perel C, Migliano ME, Aranguren M, Musso C, Farias J. Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. Revista Argentina de Endocrinología y Metabolismo. 2017 01; 54(1): 37-46. https://doi.org/10.1016/j.raem.2016.12.001

  28. Suárez González M, López Mejia VM, Eirin Rey JM, González González EL, Medina Garrido Y, Díaz Oliva SE. Enfermedad hepática grasa no alcohólica. Algunas consideraciones diagnósticas. Acta Médica del Centro. 2017; 11(2): p. Aprox. 9.

  29. Hui E, Xu A, Bo Yang H, Lam KSL. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. Journal of Diabetes Investigation. 2013 05 06; 4(5): p.413-425. https://doi.org/10.1111/jdi.12093

  30. Ahmed M. Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology. 2015; 7(11): p.1450. https://doi.org/10.4254/wjh.v7.i11.1450

  31. Zhang Q, Lu L. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015; 3: p. 78-84. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26357637

  32. Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Non-alcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. International Journal of Molecular Sciences. 2013; 14: p. 22933-22966. https://doi.org/10.3390/ijms141122933

  33. Leite N, Villela Nogueira C, Cardoso C, Salles G. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World Journal of Gastroenterol. 2014; 20(26): p. 8377-8392. https://doi.org/10.3748/wjg.v20.i26.8377

  34. Athyros V, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis D. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World Journal of Gastroenterology. 2015; 21(22): p. 6820-6834. https://doi.org/10.3748/wjg.v21.i22.6820

  35. Arab J, Candia R, Zapata R, Muñoz C, Arancibia J, Poniachik J. Management of non-alcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterol. 2014; 20(34): p. 12182-12201. https://doi.org/10.3748/wjg.v20.i34.12182

  36. Buzzeti E, Lombardi R, De Luca L, Tsochatzis E. Non-invasive assessment of fibrosis in patients with non-alcoholic fatty liver disease. International Journal of Endocrinology. 2015; 34(28): p. 1 - 9. https://doi.org/10.1155/2015/343828

  37. S B, Valbusa F, Bertolini L, Pichiri I, Montovani A, Rossi A, et al. Non-alcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 Diabetes Mellitus. Plos one. 2014 February; 9(2): p. 1 -6. https://doi.org/10.1371/journal.pone.0088371

  38. Armstrong M, Hazlehurst J, Parker R, Koushiappi E, Mann J, Sheeba K, et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. Q Journal Medical. 2014; 107: p. 33-41. https://doi.org/10.1093/qjmed/hct198

  39. Lllalukka S, Yki-Jarvinen H. Non-alcoholic fatty liver disease and risk of Type 2 diabetes. Best Practice and Research Clinical Endocrinology and Metabolism. 2016;: p. 1-11. https://doi.org/10.1016/j.beem.2016.06.006

  40. Villarejo Botija M, Prieto Zancudo C, Martín Fuertes L. Evaluación de la fibrosis en la esteatosis hepática no alcohólica con fibroscán. med gen y fam. 2015; 4(1): p. 25-29. https://doi.org/10.1016/j.mgyf.2015.05.007

  41. Spengler E, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clinic Proceedings. 2015;: p. 1233-1246. Disponible en: http://refhub.elsevier.com/S0326-4610(16)30065- 1/sbref0555. https://doi.org/10.1016/j.mayocp.2015.06.013

  42. Le S, Park S. Radiologic evaluation of non-alcoholic fatty liver disease. World Journal of Gastroenterol.. 2014; 20(23): p. 7392-73402. https://doi.org/10.3748/wjg.v20.i23.7392

  43. Singh D, Das C, Baruah M. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocrinol Metab. 2013; 17: p. 990-995. Disponible en: http://wwwpubmedcentral.nih.gov/articlerender.fcgi?artid=3872717&tool=pmcentrez&rendertype= Abstract. https://doi.org/10.4103/2230-8210.122606

  44. Csendes P, Paolinelli P, Busel D, Venturelli V, Rodríguez J. Hígado graso: ultrasonido y correlación anátomo-patológica. Rev Chil Radiol. 2004; 10(2): p. 50-52. https://doi.org/10.4067/S0717-93082004000200003

  45. Friedrich Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Rev Gastroenterol Hepatol. 2016; 13(7): p. 402-411. https://doi.org/10.1038/nrgastro.2016.86

  46. Álvarez D, Anders M. Utilidad de la Elastografía de transición (Fibroscan) en la evaluación de la fibrosis hepática en pacientes con hepatopatía crónica. Rev Med Bue Air. 2012; 72(1): p. 10-14

  47. Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.. Radiol. 2010; 256: p. 640-647. https://doi.org/10.1148/radiol.10091662

  48. Loomba R, Abraham M, Tech B, etal. Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012; 56(3): p. 943-951. https://doi.org/10.1002/hep.25772

  49. Williams C, Stengel J, Asike M, etal. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle- aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: p. 124-131. https://doi.org/10.1053/j.gastro.2010.09.038

  50. Singh S, Muir A. American Gastroenterological Association Institute Technical review on the role of Elastography in chronic liver diseases. Gastroenterol. 2017; 152(6): p. 1544-1577. https://doi.org/10.1053/j.gastro.2017.03.016

  51. Webb M, Yeshua H, Zelber Sagi S, Santo E, Brazowski E, Halpern Z, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol. 2009; 192: p. 909-914.Disponible en: http://refhub.elsevier.com/S0326- 4610(16)30065-1/sbref0495. https://doi.org/10.2214/AJR.07.4016

  52. Harshit G, Aggarwal S. Utility of Transient Elastography (FibroScan) and impact of bariatric surgery on non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg obes relat dis. 2017; 9(5).

  53. Cassinotto C, Boursier J, de Ledinghen V. Liver stiffness in non-alcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan,and ARFI with liver biopsy. Hepatol. 2016; 63(6): p. 550-557. https://doi.org/10.1002/hep.28394

  54. De Lédinghen V, Wong G. Controlled attenuation parameter for the diagnosis of steatosis in nonalcoholic fatty liver disease. Jour Gastroenterol. 2016; 31(4): p. 848-855. https://doi.org/10.1111/jgh.13219

  55. Lee H, Park S. Discrimination of non-alcoholic steatohepatitis using Transient Elastography in patients with non-alcoholic fatty liver disease. Plos One. 2016; 11(6): p. 157-358.

  56. Cequera A, García de León Méndez M. Biomarcadores para fibrosis hepática, avances, ventajas y desventajas. Rev Gastroenterol Méx. 2014; 79(3): p. 187-199. https://doi.org/10.1016/j.rgmx.2014.05.003

  57. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis. 2014; 32(1): p. 14-21. Disponible en: https://www.researchgate.net/publication/221896525_NAFLD_in_the_Absence_of_Metabolic_Sy ndrome_Different_Epidemiology_Pathogenetic_Mechanisms_Risk_Factors_for_Disease_Progre ssion.




2020     |     www.medigraphic.com